Moscow. October 29. American pharmaceutical company Pfizer and Allergan are studying the possibility of merging, which can be the biggest deal in M&A this year, according to The Wall Street Journal.
The negotiations initiated by Pfizer, are in the early stages and may end in vain.
Pfizer revenue for the latest quarter reached $12.1 billion, with growth year-on-year by 6%. Alergan sales grew in the last quarter by 10% on revenue of $5.8 billion
Allergan’s market capitalization is $112,5 billion Pfizer – $218 billion Thus, the capitalization of the combined company, which will be the largest in the industry, surpassing Johnson & Johnson, may exceed $300 billion.